Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug combination is primarily used in gastric variceal obliteration procedures. It consists of two components: * **iso-amyl-2-cyanoacrylate:** A tissue adhesive that polymerizes upon contact with blood or tissue, causing rapid occlusion of the varix. * **ethiodized oil (also known as Lipiodol or Ethiodol):** A radio-opaque contrast agent and diluent. It is derived from poppyseed oil and iodine, containing 37% iodine. In this combination, it serves as a diluent that does not affect the polymerization of cyanoacrylate, allowing for better control during injection. Its radio-opaque properties provide visualization of the mixture under fluoroscopy. Ethiodized oil is eliminated primarily via urinary excretion as inorganic iodine. The combination carries a risk of pulmonary and cerebral embolism if inadvertently injected intravascularly, which is a significant concern noted in warnings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iso-amyl-2-cyanoacrylate + ethiodized oil.